| ■ 영문 제목 : Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report By Therapy Type, By Scale (R&D), By Mode, By Workflow (Vector Production, Cell Banking), By Region, And Segment Forecasts, 2023 - 2030
|
 | ■ 상품코드 : GRV23MA080
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 1월
■ 페이지수 : 217
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 바이오
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1인 열람용) | USD5,950 ⇒환산￦8,032,500 | 견적의뢰/주문/질문 |
| Multi User (5인 열람용) | USD6,950 ⇒환산￦9,382,500 | 견적의뢰/주문/질문 |
| Global/corporate License (기업 열람용) | USD8,950 ⇒환산￦12,082,500 | 견적의뢰/구입/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
미국 Grand View Research (그랜드뷰리서치)는 세계의 세포 및 유전자 치료 제조 시장 규모가 2023년부터 2030년 사이에 연평균 26.6% 성장하여, 2030년에는 471억 달러에 달할 것으로 예측하고 있습니다. 본 조사 자료는 세계의 세포 및 유전자 치료 제조 시장을 조사대상으로 하여, 조사 방법 및 범위, 개요, 시장 변동/동향/범위, 제조사 분석, 치료 유형별 (세포 치료제, 유전자 치료제) 분석, 규모별 (상용전/연구 개발 규모 제조, 상업 규모 제조) 분석, 모드별 (수탁 제조, 사내 제조) 분석, 워크 플로우별 (세포 처리, 세포 은행, 프로세스 개발, 충전 및 마무리 조작, 기타) 분석, 지역별 (북미, 유럽, 아시아 태평양, 중남미, 중동/아프리카) 분석, 경쟁 현황 등의 내용을 게재하고 있습니다. 또한 본 자료는 Thermo Fisher Scientific, Inc., Merck Kgaa, Milliporesigma, Lonza, Catalent, Inc., Takara Bio, Inc., F. Hoffmann -La Roche Ltd., Wuxi Advanced Therapies, Samsung, Boehringer Ingelheim International Gmbh, Novartis Ag, Hitachi Chemical Co., Ltd. (Showa Denko Materials Co Ltd), Celular Therapeutics 등의 기업 정보가 포함되어 있습니다.
・조사 방법 및 범위
・개요
・시장 변동/동향/범위
・제조사 분석
・세계의 세포 및 유전자 치료 제조 시장 규모 : 치료 유형별
- 세포 치료제 제조의 시장 규모
- 유전자 치료제 제조의 시장 규모
・세계의 세포 및 유전자 치료 제조 시장 규모 : 규모별
- 상용전/연구 개발 규모 제조의 시장 규모
- 상업 규모 제조의 시장 규모
・세계의 세포 및 유전자 치료 제조 시장 규모 : 모드별
- 수탁 제조의 시장 규모
- 사내 제조의 시장 규모
・세계의 세포 및 유전자 치료 제조 시장 규모 : 워크 플로우별
- 세포 처리의 시장 규모
- 세포 은행의 시장 규모
- 프로세스 개발의 시장 규모
- 충전 및 마무리 조작의 시장 규모
- 기타 워크플로우의 시장 규모
・세계의 세포 및 유전자 치료 제조 시장 규모 : 지역별
- 북미의 세포 및 유전자 치료 제조 시장 규모
- 유럽의 세포 및 유전자 치료 제조 시장 규모
- 아시아 태평양의 세포 및 유전자 치료 제조 시장 규모
- 중남미의 세포 및 유전자 치료 제조 시장 규모
- 중동/아프리카의 세포 및 유전자 치료 제조 시장 규모
・경쟁 현황
・기업 정보 |
■ 보고서 개요Cell And Gene Therapy Manufacturing Market Growth & Trends
The global cell and gene therapy manufacturing market size is expected to reach USD 47.1 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 26.6% from 2023 to 2030 owing to the exponential progress of the clinical pipeline, coupled with a rising number of regulatory approvals for advanced therapies, which has majorly driven the growth of the market.
Significant investments by government authorities and key market players are other factors fueling the growth of cell and gene therapy manufacturing. Around USD 2.3 billion was invested in gene therapies by companies over the last decade. Major service providers, including CDMOs/CMOs and in-house manufacturers, consider these therapies as an active area of investment. For instance, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. These players are investing significant amounts either in building and/or expanding manufacturing capabilities or forming strategic alliances with competitors to boost their market presence. Thus, these factors are anticipated to act as primary driving factors for this market.
The number of cell and gene therapies entering clinical trials and later gaining marketing authorization from regulatory bodies is increasing every year. By the end of 2019, 17 cell and gene therapy products were approved by the U.S. FDA for commercial use. The U.S. FDA is expecting to receive over 200 gene and cell treatment INDs annually from the beginning of 2020. The regulatory body is also planning to approve up to 20 products per year from 2025. Such supportive government initiatives are expected to increase the demand for cell and gene therapy manufacturing services in the near future.
Following an article published in March 2020, in the U.S., the number of cell and gene therapies in the pipeline (phase III trials) was 289 at the beginning of 2019, which reached 362 in early 2020. The number is expected to increase twofold if the preclinical pipeline is considered. This growing number indicates the high demand for manufacturing services for cell and gene therapies. According to a report by America’s Biopharmaceutical Companies, gene and cell therapies range from early to late stages of clinical development with a focus on a wide spectrum of diseases, including neurologic conditions, genetic disorders, and cancer.
Cell And Gene Therapy Manufacturing Market Report Highlights
• The cell therapy manufacturing segment dominated the 2022 market in terms of revenue. A growing number of ongoing clinical trials and increasing research in this space has resulted in the segment dominance
• A high number of candidate molecules in the pre-commercial scale stage has contributed to the largest revenue share for the pre-commercial scale manufacturing market segment in 2022
• With an increasing number of regulatory approvals for gene and cell therapy products, the demand for commercial production of these therapies is increasing rapidly, thereby increasing the share of the commercial-scale manufacturing segment
• The contract manufacturing segment is expected to witness lucrative growth during the forecast period, as a substantial number of biomanufacturers are turning to CMOs for efficient and rapid product development
• Moreover, the constantly growing clinical pipeline is another contributing factor expected to accelerate contract manufacturing segment growth
• North America dominated the global market in terms of revenue owing to advancements in research and development pertaining to gene therapy and the increasing number of investments by the regional governments
• The Asia Pacific region is anticipated to grow at the fastest rate throughout the forecast period
• This can be attributed to the establishment of accelerated approval pathways, growing private and government investments, and increasing healthcare needs
■ 보고서 목차Table of Content
Chapter 1 Methodology And Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates And Forecast Timeline
1.3 Research Methodology
1.4 Information Procurement
1.4.1 Purchased Database
1.4.2 Gvr’s Internal Database
1.4.3 Secondary Sources
1.4.4 Primary Research
1.4.5 Details Of Primary Research
1.5 Information Or Data Analysis
1.5.1 Data Analysis Models
1.6 Market Formulation & Validation
1.7 Model Details
1.7.1 Commodity Flow Analysis
1.7.1.1 Approach 1: Commodity Flow Approach
1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.8 Market: CAGR Calculation
1.9 List of Secondary Sources
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
Chapter 2 Executive Summary
2.1 Competition Milieu
2.2 Segment Outlook
2.3 Market Summary, 2022 (USD Million)
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation
3.2 Parent Market Lineage
3.3 Ancillary Market Lineage
3.4 Penetration and Growth Prospect Mapping for Therapy Type, 2022
3.5 Market Dynamics
3.5.1 Market Drivers Analysis
3.5.1.1 Growing Pipeline Of Cell And Gene Therapy
3.5.1.2 Supportive Regulatory Bodies
3.5.1.3 Increase In Investment By Government And Private Players
3.5.2 Market Restraint Analysis
3.5.2.1 Technological Challenges Associated With Manufacturing
3.5.2.2 High Cost Of Manufacturing
3.5.3 Market Opportunity Analysis
3.5.3.1 Rising Pressure On Drug Developers/Manufacturers To Meet The Growing Market Demand
3.5.3.2 Expansion In Potential Markets Such As Asia Pacific And Latin America
3.5.4 Market Challenge Analysis
3.5.4.1 Lack Of Manufacturing Capacity
3.6 Swot Analysis; By Factor (Political & Legal, Economic, And Technological)
3.7 Porter’s Five Forces Analysis
3.8 Major Deals And Strategic Alliances Analysis
3.8.1 Mergers And Acquisitions
3.8.2 Technological Collaborations
3.8.3 Licensing And Partnerships
3.9 Covid-19 Impact Analysis
3.9.1 Challenge Analysis
3.9.2 Opportunity Analysis
3.9.3 Key Developments And Activities
Chapter 4 Focus On Manufacturers
4.1 Cell And Gene Therapy Manufacturing
4.1.1 Facility Expansion For Cell And Gene Therapies
4.1.2 Major Deals And Strategic Alliances Analysis
4.1.3 Mergers And Acquisitions
4.1.4 Technological Collaborations And Partnerships
4.1.5 Product Approvals And Launch
4.2 Cost Of Goods Analysis In Cell And Gene Therapy Manufacturing
4.2.1 Overall Cost Of Goods Analysis
4.2.2 Raw Material
4.2.3 Labor Costs
4.2.4 Process Costs
4.2.5 Cost Models
4.2.6 Campaign Model
4.2.7 Day Rate Model
4.2.8 Hybrid Model
4.2.9 Cost Of Goods Analysis, By Technique
4.2.10 Materials
4.2.11 Equipment
4.2.12 Personnel
4.2.13 Facility
Chapter 5 Therapy Type Business Analysis
5.1 Cell and Gene Therapy Manufacturing Market: Therapy Type Movement Analysis
5.2 Cell Therapy Manufacturing
5.2.1 Cell Therapy Manufacturing Market Estimates And Forecast, 2018 – 2030 (USD Million) (Volume, Number Of Doses)
5.2.2 Stem Cell Therapy
5.2.3 Cell Therapy Manufacturing Market Estimates And Forecast For Stem Cell Therapy, 2018 – 2030 (USD Million) (Volume, Number Of Doses)
5.2.4 Non-Stem Cell Therapy
5.2.5 Cell Therapy Manufacturing Market Estimates And Forecast For Non-Stem Cell Therapy, 2018 – 2030 (USD Million) (Volume, Number Of Doses)
5.3 Gene Therapy Manufacturing
5.3.1 Gene Therapy Manufacturing Market Estimates And Forecast, 2018 – 2030 (USD Million) (Volume, Number Of Doses)
Chapter 6 Manufacturing Scale Business Analysis
6.1 Cell And Gene Therapy Manufacturing Market: Scale Movement Analysis
6.2 Precommercial/R&D Scale Manufacturing
6.2.1 Cell And Gene Therapy Manufacturing Market Estimates And Forecast For Precommercial/R&D Scale Manufacturing, 2018 – 2030 (USD Million)
6.3 Commercial-Scale Manufacturing
6.3.1 Cell And Gene Therapy Manufacturing Market Estimates And Forecast For Commercial-Scale Manufacturing, 2018 – 2030 (USD Million)
Chapter 7 Mode Business Analysis
7.1 Cell And Gene Therapy Manufacturing Market: Mode Movement Analysis
7.2 Contract Manufacturing
7.2.1 Cell And Gene Therapy Manufacturing Market For Contract Manufacturing, 2018 – 2030 (USD Million) (Volume, Number Of Doses)
7.3 In-House Manufacturing
7.3.1 Cell And Gene Therapy Manufacturing Market For In-House Manufacturing, 2018 – 2030 (USD Million) (Volume, Number Of Doses)
Chapter 8 Workflow Business Analysis
8.1 Cell And Gene Therapy Manufacturing Market: Workflow Movement Analysis
8.2 Cell Processing
8.2.1 Cell And Gene Therapy Manufacturing Market For Cell Processing, 2018 – 2030 (USD Million)
8.3 Cell Banking
8.3.1 Cell And Gene Therapy Manufacturing Market For Cell Banking, 2018 – 2030 (USD Million)
8.4 Process Development
8.4.1 Cell And Gene Therapy Manufacturing Market For Process Development, 2018 – 2030 (USD Million)
8.5 Fill And Finish Operations
8.5.1 Cell And Gene Therapy Manufacturing Market For Fill And Finish Operations, 2018 – 2030 (USD Million)
8.6 Analytical And Quality Testing
8.6.1 Cell And Gene Therapy Manufacturing Market For Analytical And Quality Testing, 2018 – 2030 (USD Million)
8.7 Raw Material Testing
8.7.1 Cell And Gene Therapy Manufacturing Market For Raw Material Testing, 2018 – 2030 (USD Million)
8.8 Vector Production
8.8.1 Cell And Gene Therapy Manufacturing Market For Vector Production, 2018 – 2030 (USD Million)
8.9 Others
8.9.1 Cell And Gene Therapy Manufacturing Market For Others, 2018 – 2030 (USD Million)
Chapter 9 Regional Business Analysis
9.1 North America
9.1.1 Swot Analysis
9.1.1.1 North America Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.1.2 U.S.
9.1.2.1 Key Country Dynamics
9.1.2.2 Target Disease Prevalence
9.1.2.3 Competitive Scenario
9.1.2.4 Regulatory Framework
9.1.2.5 Reimbursement Scenario
9.1.2.6 U.S. Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.1.3 Canada
9.1.3.1 Key Country Dynamics
9.1.3.2 Target Disease Prevalence
9.1.3.3 Competitive Scenario
9.1.3.4 Regulatory Framework
9.1.3.5 Reimbursement Scenario
9.1.3.6 Canada Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.2 Europe
9.2.1 Swot Analysis
9.2.1.1 Europe Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.2.2 Germany
9.2.2.1 Key Country Dynamics
9.2.2.2 Target Disease Prevalence
9.2.2.3 Competitive Scenario
9.2.2.4 Regulatory Framework
9.2.2.5 Reimbursement Scenario
9.2.2.6 Germany Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.2.3 U.K.
9.2.3.1 Key Country Dynamics
9.2.3.2 Target Disease Prevalence
9.2.3.3 Competitive Scenario
9.2.3.4 Regulatory Framework
9.2.3.5 Reimbursement Scenario
9.2.3.6 UK Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.2.4 France
9.2.4.1 Key Country Dynamics
9.2.4.2 Target Disease Prevalence
9.2.4.3 Competitive Scenario
9.2.4.4 Regulatory Framework
9.2.4.5 Reimbursement Scenario
9.2.4.6 France Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.2.5 Italy
9.2.5.1 Key Country Dynamics
9.2.5.2 Target Disease Prevalence
9.2.5.3 Competitive Scenario
9.2.5.4 Regulatory Framework
9.2.5.5 Reimbursement Scenario
9.2.5.6 Italy Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.2.6 Spain
9.2.6.1 Key Country Dynamics
9.2.6.2 Target Disease Prevalence
9.2.6.3 Competitive Scenario
9.2.6.4 Regulatory Framework
9.2.6.5 Reimbursement Scenario
9.2.6.6 Spain Cell & Gene Therapy Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.2.7 Denmark
9.2.7.1 Key Country Dynamics
9.2.7.2 Target Disease Prevalence
9.2.7.3 Competitive Scenario
9.2.7.4 Regulatory Framework
9.2.7.5 Reimbursement Scenario
9.2.7.6 Denmark Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.2.8 Sweden
9.2.8.1 Key Country Dynamics
9.2.8.2 Target Disease Prevalence
9.2.8.3 Competitive Scenario
9.2.8.4 Regulatory Framework
9.2.8.5 Reimbursement Scenario
9.2.8.6 Sweden Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.2.9 Norway
9.2.9.1 Key Country Dynamics
9.2.9.2 Target Disease Prevalence
9.2.9.3 Competitive Scenario
9.2.9.4 Regulatory Framework
9.2.9.5 Reimbursement Scenario
9.2.9.6 Norway Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.3 Asia Pacific
9.3.1 SWOT Analysis
9.3.1.1 Key Region Dynamics
9.3.1.2 Asia Pacific Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.3.2 Japan
9.3.2.1 Target Disease Prevalence
9.3.2.2 Competitive Scenario
9.3.2.3 Regulatory Framework
9.3.2.4 Reimbursement Scenario
9.3.2.5 Japan Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.3.3 China
9.3.3.1 Target Disease Prevalence
9.3.3.2 Competitive Scenario
9.3.3.3 Regulatory Framework
9.3.3.4 Reimbursement Scenario
9.3.3.5 China Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.3.4 India
9.3.4.1 Target Disease Prevalence
9.3.4.2 Competitive Scenario
9.3.4.3 Regulatory Framework
9.3.4.4 Reimbursement Scenario
9.3.4.5 India Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.3.5 South Korea
9.3.5.1 Target Disease Prevalence
9.3.5.2 Competitive Scenario
9.3.5.3 Regulatory Framework
9.3.5.4 Reimbursement Scenario
9.3.5.5 South Korea Cell & Gene Therapy Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.3.6 Australia
9.3.6.1 Target Disease Prevalence
9.3.6.2 Competitive Scenario
9.3.6.3 Regulatory Framework
9.3.6.4 Reimbursement Scenario
9.3.6.5 Australia Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.3.7 Thailand
9.3.7.1 Target Disease Prevalence
9.3.7.2 Competitive Scenario
9.3.7.3 Regulatory Framework
9.3.7.4 Reimbursement Scenario
9.3.7.5 Thailand Cell & Gene Therapy Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.4 Latin America
9.4.1 Swot Analysis:
9.4.2 Key Regional Dynamics
9.4.2.1 Latin America Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.4.3 Brazil
9.4.3.1 Target Disease Prevalence
9.4.3.2 Competitive Scenario
9.4.3.3 Regulatory Framework
9.4.3.4 Reimbursement Scenario
9.4.3.5 Brazil Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.4.4 Mexico
9.4.4.1 Target Disease Prevalence
9.4.4.2 Competitive Scenario
9.4.4.3 Regulatory Framework
9.4.4.4 Reimbursement Scenario
9.4.4.5 Mexico Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.4.5 Argentina
9.4.5.1 Target Disease Prevalence
9.4.5.2 Competitive Scenario
9.4.5.3 Regulatory Framework
9.4.5.4 Reimbursement Scenario
9.4.5.5 Argentina Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
9.5 Middle East & Africa (MEA)
9.5.1 Swot Analysis
9.5.2 Key Regional Dynamics
9.5.2.1 Middle East & Africa Cell & Gene Therapy Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.5.3 South Africa
9.5.3.1 Target Disease Prevalence
9.5.3.2 Competitive Scenario
9.5.3.3 Regulatory Framework
9.5.3.4 Reimbursement Scenario
9.5.3.5 South Africa Cell & Gene Therapy Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.5.4 Saudi Arabia
9.5.4.1 Target Disease Prevalence
9.5.4.2 Competitive Scenario
9.5.4.3 Regulatory Framework
9.5.4.4 Reimbursement Scenario
9.5.4.5 Saudi Arabia Cell & Gene Therapy Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.5.5 UAE
9.5.5.1 Target Disease Prevalence
9.5.5.2 Competitive Scenario
9.5.5.3 Regulatory Framework
9.5.5.4 Reimbursement Scenario
9.5.5.5 UAE Cell & Gene Therapy Market Estimates And Forecasts, 2018 – 2030 (USD Million)
9.5.6 Kuwait
9.5.6.1 Target Disease Prevalence
9.5.6.2 Competitive Scenario
9.5.6.3 Regulatory Framework
9.5.6.4 Reimbursement Scenario
9.5.6.5 Kuwait Cell & Gene Therapy Market Estimates and Forecasts, 2018 – 2030 (USD Million)
Chapter 10 Competitive Landscape
10.1 Strategy Framework
10.2 Market Participation Categorization
10.3 Company Profiles
10.3.1 Thermo Fisher Scientific, Inc.
10.3.1.1 Company Overview
10.3.1.2 Financial Performance
10.3.1.3 Product Benchmarking
10.3.1.4 Strategic Initiatives
10.3.2 Merck Kgaa
10.3.2.1 Company Overview
10.3.2.1.1 Milliporesigma
10.3.2.2 Financial Performance
10.3.2.3 Product Benchmarking
10.3.2.4 Strategic Initiatives
10.3.3 Lonza
10.3.3.1 Company Overview
10.3.3.2 Financial Performace
10.3.3.3 Product Benchmarking
10.3.3.4 Strategic Initiatives
10.3.4 Catalent, Inc.
10.3.4.1 Company Overview
10.3.4.2 Financial Performance
10.3.4.3 Product Benchmarking
10.3.4.4 Strategic Initiatives
10.3.5 Takara Bio, Inc.
10.3.5.1 Company Overview
10.3.5.2 Financial Performance
10.3.5.3 Product Benchmarking
10.3.5.4 Strategic Initiatives
10.3.6 F. Hoffmann-La Roche Ltd.
10.3.6.1 Company Overview
10.3.6.2 Financial Performance
10.3.6.3 Product Benchmarking
10.3.6.4 Strategic Initiatives
10.3.7 Wuxi Advanced Therapies
10.3.7.1 Company Overview
10.3.7.2 Financial Performance
10.3.7.3 Product Benchmarking
10.3.7.4 Strategic Initiatives
10.3.8 Samsung
10.3.8.1 Company Overview
10.3.8.1.1 Samsung Biologics
10.3.8.2 Company Overview
10.3.8.3 Financial Performance
10.3.8.4 Product Benchmarking
10.3.8.5 Strategic Initiatives
10.3.9 Boehringer Ingelheim International Gmbh
10.3.9.1 Company Overview
10.3.9.2 Financial Performance
10.3.9.3 Product Benchmarking
10.3.9.4 Strategic Initiatives
10.3.10 Novartis Ag
10.3.10.1 Company Overview
10.3.10.2 Financial Performance
10.3.10.3 Product Benchmarking
10.3.10.4 Strategic Initiatives
10.3.11 Hitachi Chemical Co., Ltd. (Showa Denko Materials Co Ltd)
10.3.10.1 Company Overview
10.3.10.1.1 Apceth Biopharma
10.3.10.2 Company Overview
10.3.10.3 Financial Performance
10.3.10.4 Product Benchmarking
10.3.10.5 Strategic Initiatives
10.3.12 Cellular Therapeutics
10.3.12.1 Company Overview
10.3.12.2 Product Benchmarking
10.3.13 Miltenyi Biotech
10.3.13.1 Company Overview
10.3.13.2 Financial Performance
10.3.13.3 Product Benchmarking
10.3.13.4 Strategic Initiatives
10.3.14 Bluebird Bio Inc.
10.3.14.1 Company Overview
10.3.14.2 Financial Performance
10.3.14.3 Product Benchmarking
10.3.14.4 Strategic Initiatives
10.4 Recent Developments And Impact Analysis By Key Market Participants
10.5 Company Mapping
10.6 Vendor Landscape
10.6.1 List Of Key Distributors And Channel Partners
10.6.2 Key Company Market Share Analysis, 2022
10.7 Public Companies
10.7.1 Company Market Position Analysis
10.7.2 Competitive Dashboard Analysis
10.8 Private Companies
10.8.1 List Of Key Emerging Companies
10.8.2 Regional Network Map
10.8.3 Company Market Position Analysis
|
| ※본 조사보고서 [세계의 세포 및 유전자 치료 제조 시장 (2023~2030) : 연구 개발] (코드 : GRV23MA080) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 세포 및 유전자 치료 제조 시장 (2023~2030) : 연구 개발] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
